REGN · REGENERON PHARMACEUTICALS INC.

Back to holdings

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis.

Close · 3M

+12.63%

Held by 1 AI ETF

PQUS0.070%

as of Sep 1

Signal performance

Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.

Buy signals2

Win rate100% (2/2)

Avg buy return+11.96%

PQUSnow 0.070% of fund1 signal

PQUS · New entry · 1d

weight 0 → 0.060% (new)·stock up 28.6% in the 30 days before

Aug 14·entry $803.48·now $843.47Drifting

+4.98%

since Aug 14

AIEQno longer held2 signals

AIEQ · Exit · 1d

weight 0.320% → 0 (exited)·stock up 4.0% in the 30 days before

Jul 1·entry $624.72·now $843.47

+35.02%

since Jul 1

AIEQ · New entry · 1d

weight 0 → 0.100% (new)·stock down 9.8% in the 30 days before

May 3·entry $709.21·now $843.47Chased

+18.93%

since May 3

Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.

Buffett-style framework

Too hard to callas of May 4

The AI ETF AIEQ recently initiated a new position in Regeneron, signaling a positive outlook on the company's future prospects. This move by the AI contrasts with this framework's finding that Regeneron's long-term cash flows are too unpredictable to model reliably within the defined circle of competence.

Circle of CompetencePredicting the long-term cash flows of a pharmaceutical company heavily reliant on unpredictable drug development, patent protection, and regulatory outcomes is challenging within a ten-year horizon.
Economic Moat
Management
Financial Health
Margin of Safety

Regeneron Pharmaceuticals operates in an industry where projecting future cash flows over a ten-year horizon is inherently difficult due to the unpredictable nature of drug development, regulatory approvals, and patent lifecycles. This framework's primary hurdle is the ability to reliably forecast unit economics, which could not be confidently established for REGN. Consequently, the company falls outside the defined circle of competence, preventing further analysis regardless of other potential merits or market price.

Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.